Vik Bajaj. Foresite Labs

Vik Ba­jaj un­veils Fore­site's new in­cu­ba­tor, look­ing to hatch fu­ture gi­ants cross­ing tech and health­care

When it comes to har­ness­ing da­ta for health­care and the life sci­ences, a rich in­fra­struc­ture of ex­pan­sive da­ta col­lect­ed and mea­sured with the right tools are es­sen­tial to un­cov­er new in­sights and ad­vance new prod­ucts. And to build that, you need ac­cess to di­verse tal­ents backed by a pa­tient in­vestor.

Jim Tanan­baum

Just ask Vik Ba­jaj. The for­mer UC Berke­ley re­searcher first left acad­e­mia for Ver­i­ly, Google’s for­ay in­to life sci­ences, where he saw the meth­ods of mar­ry­ing com­pu­ta­tion and bi­ol­o­gy were near­ing ma­tu­ri­ty. Af­ter a few years as CSO there he moved on to Grail work­ing to­wards the ear­ly de­tec­tion of can­cer — an­oth­er da­ta in­ten­sive en­deav­or — be­fore land­ing his cur­rent role as man­ag­ing di­rec­tor of Fore­site Cap­i­tal.

Yet in spite of all the progress he’s seen and helped prop­a­gate, it’s not quite there yet. There is still a gap be­tween what’s cur­rent­ly avail­able and what he sees as a trans­for­ma­tion in health­care en­abled by the in­for­ma­tion rev­o­lu­tion.

“Re­al­ly what we per­ceive — and ob­vi­ous­ly I’m not alone in stat­ing this — is that there is an eco­nom­ic cri­sis in our health­care sys­tem where we are spend­ing so much of our na­tion­al prod­uct on health­care and yet we have out­comes that are ac­tu­al­ly in de­cline in many pop­u­la­tions,” Ba­jaj told End­points News. “And we think that there are many ways to make that in­dus­try more ef­fi­cient and more re­spon­sive to the needs of its pa­tients, but ob­vi­ous­ly this idea of us­ing da­ta sci­ence, the pow­er of mea­sure­ments, of un­der­stand­ing of ex­per­i­ments is fun­da­men­tal to gen­er­at­ing re­li­able ev­i­dence that will solve some of these large health­care prob­lems.”

The no­tion is what spurred him and Fore­site CEO Jim Tanan­baum to launch Fore­site Labs, an en­tre­pre­neur­ial in­cu­ba­tor de­signed to nur­ture some of the foun­da­tion­al com­pa­nies at the nexus of da­ta sci­ence and health­care.

Fore­site Labs re­moves three of the biggest bar­ri­ers for star­tups in this space, ac­cord­ing to Ba­jaj: It of­fers a pool of pub­lic and pro­pri­etary datasets, which would be ex­pen­sive for any one com­pa­ny to gen­er­ate; an analy­sis plat­form con­sist­ing of the lead­ing tools to aid with clin­i­cal ap­pli­ca­tion of da­ta; as well as a sea­soned team of 20-plus — be­tween the Boston and San Fran­cis­co of­fices — to of­fer sci­en­tif­ic, tech­ni­cal and busi­ness sup­port. As part of that, they al­so hook com­pa­nies up with part­ners for re­sources such as lab space.

Cor­re­spond­ing­ly, he sees three types of ven­tures that would ben­e­fit the most from their in­cu­ba­tion — and that they would be most in­ter­est­ed in.

The first in­volves ther­a­peu­tic op­por­tu­ni­ties cen­tered around func­tion­al ge­nomics; the sec­ond group build the in­fra­struc­ture need­ed for clin­i­cal de­vel­op­ment us­ing re­al-world ev­i­dence; the third cat­e­go­ry would look in­to per­son­al­ized health­care de­liv­ery based on in­di­vid­ual as­sess­ment of dis­ease risk.

Out­side of these high lev­el de­tails, though, he’s let­ting lit­tle else slip about what Fore­site Labs has been work­ing on over the past year. The cap­i­tal Fore­site has to de­ploy, the num­ber of ven­tures they would back at any one time, the ca­pa­bil­i­ties they are con­sid­er­ing adding — these are all stay­ing un­der wraps.

One thing we know, though, is that Fore­site has plen­ty of fire­pow­er and pa­tience to seed com­pa­nies where they see po­ten­tial. Last May the firm closed its fourth fund at a record $668 mil­lion and vowed to beef up their ma­chine learn­ing chops to en­able bet­ter in­vest­ment de­ci­sions.

“We’re get­ting in­to this area where we be­lieve through long ex­pe­ri­ence has tremen­dous po­ten­tial,” he said. “But it’s a po­ten­tial that will be re­al­ized rough­ly over the next decade. […] That means that we’re go­ing to be ini­tial­ly very mea­sured in what we do, and very de­lib­er­ate in launch­ing a few high qual­i­ty com­pa­nies with­out putting num­bers or tar­gets on it.”

The team of ex­perts they’ve re­cruit­ed to Fore­site Labs, he added, should prove to be the great­est as­set over the long run. They in­clude:

  • Alex Block­er, head of da­ta sci­ence (for­mer­ly of Grail and Ver­i­ly)
  • Rick Dewey, head of ge­nomics dis­cov­ery (for­mer­ly of the Re­gen­eron Ge­net­ics Cen­ter)
  • Damien Soghoian, head of op­er­a­tions and strat­e­gy (for­mer­ly of Ver­i­ly)
  • Paul Da Sil­va Jar­dine, head of drug dis­cov­ery (for­mer­ly of Pfiz­er)

On top of that, he’s as­sem­bled a star-stud­ded sci­en­tif­ic ad­vi­so­ry board fea­tur­ing Math­ai Mam­men of J&J, Pao­la Ar­lot­ta of Har­vard, Eu­an Ash­ley of Stan­ford, Calum MacRae of Brigham and Women’s Hos­pi­tal, Steve Finkbein­er of Glad­stone, Jeff Hu­ber and Alex Ar­a­va­nis of Grail, as well as Rus­lan Medzhi­tov of the Howard Hugh­es Med­ical In­sti­tute.

“Ob­vi­ous­ly it will be an area that will be much big­ger than what Fore­site Labs does, but I think that we are a lit­tle bit ahead and so poised to have a huge in­flu­ence over the trans­for­ma­tion,” Ba­jaj said.

BiTE® Plat­form and the Evo­lu­tion To­ward Off-The-Shelf Im­muno-On­col­o­gy Ap­proach­es

Despite rapid advances in the field of immuno-oncology that have transformed the cancer treatment landscape, many cancer patients are still left behind.1,2 Not every person has access to innovative therapies designed specifically to treat his or her disease. Many currently available immuno-oncology-based approaches and chemotherapies have brought long-term benefits to some patients — but many patients still need other therapeutic options.3

As it hap­pened: A bid­ding war for an an­tibi­ot­ic mak­er in a mar­ket that has rav­aged its peers

In a bewildering twist to the long-suffering market for antibiotics — there has actually been a bidding war for an antibiotic company: Tetraphase.

It all started back in March, when the maker of Xerava (an FDA approved therapy for complicated intra-abdominal infections) said it had received an offer from AcelRx for an all-stock deal valued at $14.4 million.

The offer was well-timed. Xerava was approved in 2018, four years after Tetraphase posted its first batch of pivotal trial data, and sales were nowhere near where they needed to be in order for the company to keep its head above water.

Mer­ck wins a third FDA nod for an­tibi­ot­ic; Mereo tack­les TIG­IT with $70M raise in hand

Merck — one of the last big pharma bastions in the beleaguered field of antibiotic drug development — on Friday said the FDA had signed off on using its combination drug, Recarbrio, with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The drug could come handy for use in hospitalized patients who are afflicted with Covid-19, who carry a higher risk of contracting secondary bacterial infections. Once SARS-CoV-2, the virus behind Covid-19, infects the airways, it engages the immune system, giving other pathogens free rein to pillage and plunder as they please — the issue is particularly pertinent in patients on ventilators, which in any case are breeding grounds for infectious bacteria.

RA Cap­i­tal, Hill­house join $310M rush to back Ever­est's climb to com­mer­cial heights in Chi­na

Money has never been an issue for Everest Medicines. With an essentially open tab from their founders at C-Bridge Capital, the biotech has gone two and a half years racking up drug after drug, bringing in top exec after top exec, and issuing clinical update after update.

But now other investors want in — and they’re betting big.

Everest is closing its Series C at $310 million. The first $50 million comes from the Jiashan National Economic and Technological Development Zone; the remaining C-2 tranche was led by Janchor Partners, with RA Capital Management and Hillhouse Capital as co-leaders. Decheng Capital, GT Fund, Janus Henderson Investors, Rock Springs Capital, Octagon Investments all joined.

Drug man­u­fac­tur­ing gi­ant Lon­za taps Roche/phar­ma ‘rein­ven­tion’ vet as its new CEO

Lonza chairman Albert Baehny took his time headhunting a new CEO for the company, making it absolutely clear he wanted a Big Pharma or biotech CEO with a good long track record in the business for the top spot. In the end, he went with the gold standard, turning to Roche’s ranks to recruit Pierre-Alain Ruffieux for the job.

Ruffieux, a member of the pharma leadership team at Roche, spent close to 5 years at the company. But like a small army of manufacturing execs, he gained much of his experience at the other Big Pharma in Basel, remaining at Novartis for 12 years before expanding his horizons.

President Donald Trump (left) and Moncef Slaoui, head of Operation Warp Speed (Alex Brandon, AP Images)

UP­DAT­ED: White House names fi­nal­ists for Op­er­a­tion Warp Speed — with 5 ex­pect­ed names and one no­table omis­sion

A month after word first broke of the Trump Administration’s plan to rapidly accelerate the development and production of a Covid-19 vaccine, the White House has selected the five vaccine candidates they consider most likely to succeed, The New York Times reported.

Most of the names in the plan, known as Operation Warp Speed, will come as little surprise to those who have watched the last four months of vaccine developments: Moderna, which was the first vaccine to reach humans and is now the furthest along of any US effort; J&J, which has not gone into trials but received around $500 million in funding from BARDA earlier this year; the joint AstraZeneca-Oxford venture which was granted $1.2 billion from BARDA two weeks ago; Pfizer, which has been working with the mRNA biotech BioNTech; and Merck, which just entered the race and expects to put their two vaccine candidates into humans later this year.

Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — with $750M from CEPI, Gavi

Another Big Pharma is entering the Covid-19 antibody hunt.

AbbVie has announced a collaboration with the Netherlands’ Utrecht University and Erasmus Medical Center and the Chinese-Dutch biotech Harbour Biomed to develop a neutralizing antibody that can treat Covid-19. The antibody, called 47D11, was discovered by AbbVie’s three partners, and AbbVie will support early preclinical work, while preparing for later preclinical and clinical development. Researchers described the antibody in Nature Communications last month.

David Meline (file photo)

Mod­er­na’s new CFO took a cut in salary to jump to the mR­NA rev­o­lu­tion­ary. But then there’s the rest of the com­pen­sa­tion pack­age

David Meline took a little off the top of his salary when he jumped from the CFO post at giant Amgen to become the numbers czar at the upstart vaccines revolutionary Moderna. But the SEC filing that goes with a major hire also illustrates how it puts him in line for a fortune — provided the biotech player makes good as a promising game changer.

To be sure, there’s nothing wrong with the base salary: $600,000. Or the up-to 50% annual cash bonus — an industry standard — that comes with it. True, the 62-year-old earned $999,000 at Amgen in 2019, but it’s the stock options that really count in the current market bliss for all things biopharma. And there Meline did well.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,100+ biopharma pros reading Endpoints daily — and it's free.

Por­tion of Neil Wood­ford’s re­main­ing in­vest­ments, in­clud­ing Nanopore, sold off for $284 mil­lion

It’s been precisely one year and one day since Neil Woodford froze his once-vaunted fund, and while a global pandemic has recently shielded him from the torrent of headlines, the fallout continues.

Today, the California-based patent licensing firm Acacia Research acquired the fund’s shares for 19 healthcare and biotech companies for $284 million.  Those companies include shares for public and private companies and count some of Woodford’s most prominent bio-bets, such as Theravance Biopharma, Oxford Nanopore and Mereo Biopharma, according to Sky News, which first reported the sale. It won’t include shares for BenevelontAI, the machine learning biotech once valued at $2 billion.